OBJECTIVE:To observe the effect of ulinastatin on the serum inflammatory cytokines of patients with ulcerative colitis. METHODS:Totally 60 patients with ulcerative colitis were randomly divided into observation group and test group,and an-other 20 healthy volunteers were selected as normal control group. Test group were received routine treatment,including nutrition support and maintaining water,electrolyte balance and 5-amino salicylic acid (5-ASA),etc. Patients in observation group were treated by ulinastatin 200 000 U by intravenous infusion based on the treatment of test group,q12h. 7 d were as a course for the pa-tients,and it lasted for 2 courses. The clinical data in healthy control group and other 2 groups was observed,including tumor ne-crosis factor-α(TNF-α),interleukin-1β(IL-1β),IL-8,C-reactive protein(CRP)levels,colon peroxidase activity(MPO),clinical activity index(CAI)scores and the incidence of adverse reactions before and after treatment. RESULTS:Before and after treatment, the TNF-α,IL-1β,IL-8,CRP and MPO in other 2 groups were significantly higher than health control group,with significant dif-ferences(P<0.05). After treatment,the TNF-α and IL-1β in 2 groups and the IL-8 and CRP levels in observation group were low than before,and the TNF-α,IL-8 and CRP levels in observation group were significantly lower than test group,with significant dif-ferences(P<0.05). There were no obvious adverse reactions during treatment. CONCLUSIONS:Based on the routine treatment, ulinastatin can effectively inhibit the expression of inflammatory cytokines of patients with ulcerative colitis,and relieve the inflam-mation and injury of colon,with good safety.